<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03661346</url>
  </required_header>
  <id_info>
    <org_study_id>15-0309</org_study_id>
    <nct_id>NCT03661346</nct_id>
  </id_info>
  <brief_title>Esmolol vs. Labetalol in Endoscopic Sinus Surgery</brief_title>
  <official_title>Blood Loss and Visibility With Esmolol vs. Labetalol in Endoscopic Sinus Surgery: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare esmolol and labetalol bleeding and intra-operative&#xD;
      visibility scores in functional endoscopic sinus surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Improved intraoperative visibility during functional endoscopic sinus surgery&#xD;
      (FESS) decreases the risk of serious orbital or skull base injuries. Beta blockers are among&#xD;
      several methods used to reduce mean arterial pressure (MAP), heart rate (HR) and mucosal&#xD;
      bleeding. Labetalol (mixed alpha-1-beta blocker) reduces HR and MAP; however, its alpha-1&#xD;
      blockade may mitigate topical epinephrine decongestant effects. Esmolol (selective beta-1&#xD;
      blocker) does not have direct antagonistic effects on topical epinephrine. This study&#xD;
      compares the hemodynamic parameters (rate of blood loss, MAP control, HR) and intraoperative&#xD;
      visibility during FESS between esmolol and labetalol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">March 30, 2018</completion_date>
  <primary_completion_date type="Actual">March 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-operative Surgical Visibility - Boezaart Scale</measure>
    <time_frame>Duration of operation</time_frame>
    <description>Standardized scoring systems used by surgeons to rate surgical field quality in FESS:&#xD;
Boezaart scale (0-5):&#xD;
0 = no bleeding (optimal)&#xD;
= slight bleeding with no suction required&#xD;
= slight bleeding with occasional suctioning required&#xD;
= slight bleeding with frequent suctioning required&#xD;
= moderate bleeding with frequent suctioning required and surgical field visibility is compromised when suctioning is removed&#xD;
= severe bleeding (worst) with constant suctioning required and compromised view</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-operative Surgical Visibility - Wormald Scale</measure>
    <time_frame>Duration of operation up to 3 hours</time_frame>
    <description>Standardized scoring systems used by surgeons to rate surgical field quality in FESS:&#xD;
Wormald scale (0-10):&#xD;
0 = No bleeding (optimal)&#xD;
= 1-2 points of blood ooze&#xD;
= 3-4 points of ooze&#xD;
= 5-6 points of ooze&#xD;
= 7-8 points of ooze&#xD;
= 9-10 points of ooze&#xD;
= &gt;10 points of ooze, obscuring field&#xD;
= Mild field bleeding with slow post-nasal accumulation&#xD;
= Moderate field bleeding with moderate post-nasal accumulation&#xD;
= Moderate-severe field bleeding with rapid post-nasal accumulation&#xD;
= Severe bleeding (worst) with nose filling rapidly</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Blood Loss</measure>
    <time_frame>Duration of operation up to 3 hours</time_frame>
    <description>milliliters per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Mean Arterial Blood Pressure</measure>
    <time_frame>Duration of operation up 3 hours/completion of operation</time_frame>
    <description>units of mmHg, measured throughout operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Heart Rate</measure>
    <time_frame>Duration of operation up to 3 hours/completion of surgery</time_frame>
    <description>units of beats per minute, measured throughout the operation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Chronic Sinusitis</condition>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving esmolol when intra-operative MAP &gt; 80 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Labetalol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving labetalol when intra-operative MAP &gt; 80 mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Labetalol</intervention_name>
    <description>Aliquots of 20mg of Labetol&#xD;
• Maximum Dose - 300mg total for case</description>
    <arm_group_label>Labetalol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>Infusion - 0.1mg/kg/min&#xD;
• Maximum Dose - after 30 minutes, 0.3mg/kg/min</description>
    <arm_group_label>Esmolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of CRS with or without nasal polyps&#xD;
&#xD;
          -  Undergoing FESS for CRS&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status 1 (healthy) or 2 (patient&#xD;
             with mild systemic disease).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  COPD&#xD;
&#xD;
          -  Bradycardia&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  End stage renal disease&#xD;
&#xD;
          -  Cerebrovascular accident&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Preoperative use of NSAIDs, aspirin, or beta-blockers&#xD;
&#xD;
          -  Body mass index (BMI) greater than 40 kg/m2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad Chaaban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <results_first_submitted>May 20, 2019</results_first_submitted>
  <results_first_submitted_qc>January 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2021</results_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labetalol</mesh_term>
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>3 months to 3 years at time of publication (if applicable)</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03661346/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 23, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03661346/Prot_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03661346/ICF_004.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Esmolol</title>
          <description>Patients receiving esmolol when intra-operative MAP &gt; 80 mmHg.&#xD;
Esmolol: Infusion - 0.1mg/kg/min&#xD;
• Maximum Dose - after 30 minutes, 0.3mg/kg/min</description>
        </group>
        <group group_id="P2">
          <title>Labetalol</title>
          <description>Patients receiving labetalol when intra-operative MAP &gt; 80 mmHg&#xD;
Labetalol: Aliquots of 20mg of Labetol&#xD;
• Maximum Dose - 300mg total for case</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13">Esmolol administration</participants>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with chronic rhinosinusitis undergoing FESS</population>
      <group_list>
        <group group_id="B1">
          <title>Esmolol</title>
          <description>Patients receiving esmolol when intra-operative MAP &gt; 80 mmHg.&#xD;
Esmolol: Infusion - 0.1mg/kg/min&#xD;
• Maximum Dose - after 30 minutes, 0.3mg/kg/min</description>
        </group>
        <group group_id="B2">
          <title>Labetalol</title>
          <description>Patients receiving labetalol when intra-operative MAP &gt; 80 mmHg&#xD;
Labetalol: Aliquots of 20mg of Labetol&#xD;
• Maximum Dose - 300mg total for case</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="17"/>
                    <measurement group_id="B2" value="51" spread="16"/>
                    <measurement group_id="B3" value="50" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intra-operative Surgical Visibility - Boezaart Scale</title>
        <description>Standardized scoring systems used by surgeons to rate surgical field quality in FESS:&#xD;
Boezaart scale (0-5):&#xD;
0 = no bleeding (optimal)&#xD;
= slight bleeding with no suction required&#xD;
= slight bleeding with occasional suctioning required&#xD;
= slight bleeding with frequent suctioning required&#xD;
= moderate bleeding with frequent suctioning required and surgical field visibility is compromised when suctioning is removed&#xD;
= severe bleeding (worst) with constant suctioning required and compromised view</description>
        <time_frame>Duration of operation</time_frame>
        <population>Those analyzed had complete data</population>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Patients receiving esmolol when intra-operative MAP &gt; 80 mmHg.&#xD;
Esmolol: Infusion - 0.1mg/kg/min&#xD;
• Maximum Dose - after 30 minutes, 0.3mg/kg/min</description>
          </group>
          <group group_id="O2">
            <title>Labetalol</title>
            <description>Patients receiving labetalol when intra-operative MAP &gt; 80 mmHg&#xD;
Labetalol: Aliquots of 20mg of Labetol&#xD;
• Maximum Dose - 300mg total for case</description>
          </group>
        </group_list>
        <measure>
          <title>Intra-operative Surgical Visibility - Boezaart Scale</title>
          <description>Standardized scoring systems used by surgeons to rate surgical field quality in FESS:&#xD;
Boezaart scale (0-5):&#xD;
0 = no bleeding (optimal)&#xD;
= slight bleeding with no suction required&#xD;
= slight bleeding with occasional suctioning required&#xD;
= slight bleeding with frequent suctioning required&#xD;
= moderate bleeding with frequent suctioning required and surgical field visibility is compromised when suctioning is removed&#xD;
= severe bleeding (worst) with constant suctioning required and compromised view</description>
          <population>Those analyzed had complete data</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread=".69"/>
                    <measurement group_id="O2" value="3.1" spread=".89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intra-operative Surgical Visibility - Wormald Scale</title>
        <description>Standardized scoring systems used by surgeons to rate surgical field quality in FESS:&#xD;
Wormald scale (0-10):&#xD;
0 = No bleeding (optimal)&#xD;
= 1-2 points of blood ooze&#xD;
= 3-4 points of ooze&#xD;
= 5-6 points of ooze&#xD;
= 7-8 points of ooze&#xD;
= 9-10 points of ooze&#xD;
= &gt;10 points of ooze, obscuring field&#xD;
= Mild field bleeding with slow post-nasal accumulation&#xD;
= Moderate field bleeding with moderate post-nasal accumulation&#xD;
= Moderate-severe field bleeding with rapid post-nasal accumulation&#xD;
= Severe bleeding (worst) with nose filling rapidly</description>
        <time_frame>Duration of operation up to 3 hours</time_frame>
        <population>Those included had complete data</population>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Patients receiving esmolol when intra-operative MAP &gt; 80 mmHg.&#xD;
Esmolol: Infusion - 0.1mg/kg/min&#xD;
• Maximum Dose - after 30 minutes, 0.3mg/kg/min</description>
          </group>
          <group group_id="O2">
            <title>Labetalol</title>
            <description>Patients receiving labetalol when intra-operative MAP &gt; 80 mmHg&#xD;
Labetalol: Aliquots of 20mg of Labetol&#xD;
• Maximum Dose - 300mg total for case</description>
          </group>
        </group_list>
        <measure>
          <title>Intra-operative Surgical Visibility - Wormald Scale</title>
          <description>Standardized scoring systems used by surgeons to rate surgical field quality in FESS:&#xD;
Wormald scale (0-10):&#xD;
0 = No bleeding (optimal)&#xD;
= 1-2 points of blood ooze&#xD;
= 3-4 points of ooze&#xD;
= 5-6 points of ooze&#xD;
= 7-8 points of ooze&#xD;
= 9-10 points of ooze&#xD;
= &gt;10 points of ooze, obscuring field&#xD;
= Mild field bleeding with slow post-nasal accumulation&#xD;
= Moderate field bleeding with moderate post-nasal accumulation&#xD;
= Moderate-severe field bleeding with rapid post-nasal accumulation&#xD;
= Severe bleeding (worst) with nose filling rapidly</description>
          <population>Those included had complete data</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="1.7"/>
                    <measurement group_id="O2" value="5.9" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Blood Loss</title>
        <description>milliliters per minute</description>
        <time_frame>Duration of operation up to 3 hours</time_frame>
        <population>Those included had complete data</population>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Patients receiving esmolol when intra-operative MAP &gt; 80 mmHg.&#xD;
Esmolol: Infusion - 0.1mg/kg/min&#xD;
• Maximum Dose - after 30 minutes, 0.3mg/kg/min</description>
          </group>
          <group group_id="O2">
            <title>Labetalol</title>
            <description>Patients receiving labetalol when intra-operative MAP &gt; 80 mmHg&#xD;
Labetalol: Aliquots of 20mg of Labetol&#xD;
• Maximum Dose - 300mg total for case</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Blood Loss</title>
          <description>milliliters per minute</description>
          <population>Those included had complete data</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".59" spread=".28"/>
                    <measurement group_id="O2" value=".66" spread=".37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Mean Arterial Blood Pressure</title>
        <description>units of mmHg, measured throughout operation</description>
        <time_frame>Duration of operation up 3 hours/completion of operation</time_frame>
        <population>Those included had complete data</population>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Patients receiving esmolol when intra-operative MAP &gt; 80 mmHg.&#xD;
Esmolol: Infusion - 0.1mg/kg/min&#xD;
• Maximum Dose - after 30 minutes, 0.3mg/kg/min</description>
          </group>
          <group group_id="O2">
            <title>Labetalol</title>
            <description>Patients receiving labetalol when intra-operative MAP &gt; 80 mmHg&#xD;
Labetalol: Aliquots of 20mg of Labetol&#xD;
• Maximum Dose - 300mg total for case</description>
          </group>
        </group_list>
        <measure>
          <title>Average Mean Arterial Blood Pressure</title>
          <description>units of mmHg, measured throughout operation</description>
          <population>Those included had complete data</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7" spread="7.5"/>
                    <measurement group_id="O2" value="79.4" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Heart Rate</title>
        <description>units of beats per minute, measured throughout the operation</description>
        <time_frame>Duration of operation up to 3 hours/completion of surgery</time_frame>
        <population>Those included had complete data</population>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Patients receiving esmolol when intra-operative MAP &gt; 80 mmHg.&#xD;
Esmolol: Infusion - 0.1mg/kg/min&#xD;
• Maximum Dose - after 30 minutes, 0.3mg/kg/min</description>
          </group>
          <group group_id="O2">
            <title>Labetalol</title>
            <description>Patients receiving labetalol when intra-operative MAP &gt; 80 mmHg&#xD;
Labetalol: Aliquots of 20mg of Labetol&#xD;
• Maximum Dose - 300mg total for case</description>
          </group>
        </group_list>
        <measure>
          <title>Average Heart Rate</title>
          <description>units of beats per minute, measured throughout the operation</description>
          <population>Those included had complete data</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" spread="8.7"/>
                    <measurement group_id="O2" value="69" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected following surgery in recovery room</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Esmolol</title>
          <description>Patients receiving esmolol when intra-operative MAP &gt; 80 mmHg.&#xD;
Esmolol: Infusion - 0.1mg/kg/min&#xD;
• Maximum Dose - after 30 minutes, 0.3mg/kg/min</description>
        </group>
        <group group_id="E2">
          <title>Labetalol</title>
          <description>Patients receiving labetalol when intra-operative MAP &gt; 80 mmHg&#xD;
Labetalol: Aliquots of 20mg of Labetol&#xD;
• Maximum Dose - 300mg total for case</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mohamad Chaaban</name_or_title>
      <organization>University of Texas Medical Branch - Galveston</organization>
      <phone>281-338-0829</phone>
      <email>mrchaaba@UTMB.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

